Latest Acorda Therapeutics (ACOR) Headlines Fin
Post# of 74
Posted On: 03/12/2014 5:25:59 PM
Latest Acorda Therapeutics (ACOR) Headlines
Financial Results, FDA Reviews, and Share Price Movements - Analyst Notes on Insys, Oxygen Biotherapeutics, Acorda, Air Methods, and AcelRx
PR Newswire - Fri Mar 07, 7:00AM CST
Today, Analysts Review released its analysts' notes regarding INSYS Therapeutics, Inc. (NASDAQ: INSY), Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT), Acorda Therapeutics, Inc. (NASDAQ: ACOR), Air Methods Corp. (NASDAQ: AIRM), and AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Uptrend Call Working As Acorda Therapeutics Stock Rises 26.2% (ACOR)
Comtex SmarTrend(R) - Thu Mar 06, 9:52AM CST
SmarTrend identified an Uptrend for Acorda Therapeutics (NASDAQ:ACOR) on February 12th, 2014 at $30.98. In approximately 3 weeks, Acorda Therapeutics has returned 26.17% as of today's recent price of $39.09.
Acorda Therapeutics (ACOR) Jumps: Stock Rises 7.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 05, 8:18AM CST
Acorda Therapeutics, Inc. (ACOR) was a big mover last session, as the company saw its shares rise by roughly 8% on the day.
Acorda Therapeutics (ACOR) Marked As A Barbarian At The Gate
at The Street - Tue Mar 04, 11:41AM CST
Trade-Ideas LLC identified Acorda Therapeutics (ACOR) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate
Shares of ACOR Up 18.3% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Feb 27, 9:23AM CST
SmarTrend identified an Uptrend for Acorda Therapeutics (NASDAQ:ACOR) on February 12th, 2014 at $30.98. In approximately 2 weeks, Acorda Therapeutics has returned 18.30% as of today's recent price of $36.65.
Acorda Therapeutics to Present at the Cowen & Company 34th Annual Health Care Conference
Business Wire - Wed Feb 26, 6:00AM CST
Acorda Therapeutics, Inc. (Nasdaq:ACOR) announced that Ron Cohen, M.D., Acorda's President and Chief Executive Officer, and Mike Rogers, Acorda's Chief Financial Officer, will present at the Cowen & Company 34th Annual Health Care Conference on Monday, March 3 at 4:10 pm ET at the Marriott Copley Plaza Hotel in Boston.
BioLineRx appoints Dr Sandra Panem to board
M2 - Tue Feb 25, 5:59AM CST
Biopharmaceutical company BioLineRx (NASDAQ:BLRX)(TASE:BLRX), headquartered in Israel, revealed on Monday the addition of Dr Sandra Panem PhD to its board of directors.
BioLineRx Appoints Dr. Sandra Panem to Board of Directors
PR Newswire - Mon Feb 24, 6:00AM CST
BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today the appointment of Sandra Panem, Ph.D., to its Board of Directors.
Acorda Up After Q4 Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 18, 1:53PM CST
Acorda misses Q4 earnings estimates
Acorda Therapeutics to Present at Citi 2014 Global Healthcare and RBC Capital Markets Conferences in February
Business Wire - Tue Feb 18, 6:00AM CST
Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that it will present at the Citi 2013 Global Healthcare and RBC Capital Markets conferences in February.
Acorda Therapeutics (ACOR) Soars: Stock Adds 10% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 14, 7:51AM CST
Acorda Therapeutics, Inc. was a big mover last session, as its shares rose over 10% on the day.
Left Ventricular Dysfunction - Pipeline Review, H2 2013 Research Report
M2 - Fri Feb 14, 2:51AM CST
Research and Markets (http://www.researchandmarkets.com/research/45g5zb/left_ventricular) has announced the addition of the "Left Ventricular Dysfunction - Pipeline Review, H2 2013" report to their offering. 'Left Ventricular Dysfunction - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Left Ventricular Dysfunction, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Left Ventricular Dysfunction. Scope - A snapshot of the global therapeutic scenario for Left Ventricular Dysfunction. - A review of the Left Ventricular Dysfunction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Left Ventricular Dysfunction pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Left Ventricular Dysfunction Overview Therapeutics Development Pipeline Products for Left Ventricular Dysfunction - Overview Pipeline Products for Left Ventricular Dysfunction - Comparative Analysis Late Stage Products Clinical Stage Products Early Stage Products Assessment by Monotherapy Products Drug Profiles carvedilol CR - Drug Profile carvedilol CR - Drug Profile omecamtiv mecarbil - Drug Profile bromocriptine - Drug Profile CAP-1002 - Drug Profile cimaglermin alfa - Drug Profile CPI-003 - Drug Profile DIOHF - Drug Profile carvedilol CR - Drug Profile Product Description Mechanism of Action R&D Progress Featured News & Press Releases Companies Mentioned Amgen Inc. Acorda Therapeutics, Inc. Innopharmax Inc. RedHill Biopharma Ltd. Capricor Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/45...entricular About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Acorda Therapeutics, The Medicines Co. and Shire Plc Could Be Big Movers in Healthcare Today
George Budwell, The Motley Fool - Motley Fool - Thu Feb 13, 8:36AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Good morning, fellow Foolish investors! It's time to check in...
Acorda Therapeutics Reports Fourth Quarter and Full Year 2013 Financial Results
Business Wire - Thu Feb 13, 5:00AM CST
--Year-End Cash, Cash Equivalents and Short-Term Investments of $367.2 Million
Will Zoetis (ZTS) Miss Estimates in Q4? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 10, 11:50AM CST
Zoetis is set to report fourth quarter and full year 2013 results on Feb 11 before the opening bell.
Acorda Therapeutics to Present at the Leerink Global Healthcare Conference
Business Wire - Fri Feb 07, 6:00AM CST
Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that Ron Cohen, M.D., President & CEO, will present at the Leerink Global Healthcare Conference on Thursday, February 13, 2014 at 11:35 a.m. at The Waldorf Astoria Hotel in New York.
Acorda Therapeutics to Host Conference Call to Discuss Fourth Quarter and Year End 2013 Financial Results on February 13, 2014
Business Wire - Thu Feb 06, 6:00AM CST
Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that it will host a conference call and live webcast to report its fourth quarter and year end 2013 financial results on Thursday, February 13 at 8:30 a.m. ET.
Eguana Delivering Strategic Targets: Company Files Annual Financial Statements and Provides Operations Update
Marketwire - Thu Jan 30, 2:35PM CST
Eguana Technologies Inc. (TSX VENTURE: EGT) ("Eguana" or the Company"), a leading supplier of high performance power conversion and control systems for "smart grid" and "micro-grid" energy storage applications announced that it has filed its Consolidated Financial Statements for the year ending September 30, 2013, along with Management's Discussion and Analysis thereof. The Consolidated Financial Statements and the Management Discussion and Analysis thereof are available on SEDAR at www.sedar.com and on the Company's website at www.eguanatech.com.
Jazz Pharmaceuticals Isn't Tired of Spending Money
Todd Campbell, The Motley Fool - Motley Fool - Tue Jan 14, 5:30PM CST
Jazz Pharmaceuticals, which spent nearly $1 billion buying orphan drug maker Gentium in December, just inked another deal to lock up Aerial BioPharma's promising mid stage narcolepsy drug, ADX-N05 Jazz is giving Ariel -- a small...
ACOR Preliminary Q4 Revs Look Good - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 14, 10:40AM CST
Ampyra sales improved on a sequential basis.
Financial Results, FDA Reviews, and Share Price Movements - Analyst Notes on Insys, Oxygen Biotherapeutics, Acorda, Air Methods, and AcelRx
PR Newswire - Fri Mar 07, 7:00AM CST
Today, Analysts Review released its analysts' notes regarding INSYS Therapeutics, Inc. (NASDAQ: INSY), Oxygen Biotherapeutics, Inc. (NASDAQ: OXBT), Acorda Therapeutics, Inc. (NASDAQ: ACOR), Air Methods Corp. (NASDAQ: AIRM), and AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Uptrend Call Working As Acorda Therapeutics Stock Rises 26.2% (ACOR)
Comtex SmarTrend(R) - Thu Mar 06, 9:52AM CST
SmarTrend identified an Uptrend for Acorda Therapeutics (NASDAQ:ACOR) on February 12th, 2014 at $30.98. In approximately 3 weeks, Acorda Therapeutics has returned 26.17% as of today's recent price of $39.09.
Acorda Therapeutics (ACOR) Jumps: Stock Rises 7.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 05, 8:18AM CST
Acorda Therapeutics, Inc. (ACOR) was a big mover last session, as the company saw its shares rise by roughly 8% on the day.
Acorda Therapeutics (ACOR) Marked As A Barbarian At The Gate
at The Street - Tue Mar 04, 11:41AM CST
Trade-Ideas LLC identified Acorda Therapeutics (ACOR) as a "barbarian at the gate" (strong stocks crossing above resistance with today's range greater than 200%) candidate
Shares of ACOR Up 18.3% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Thu Feb 27, 9:23AM CST
SmarTrend identified an Uptrend for Acorda Therapeutics (NASDAQ:ACOR) on February 12th, 2014 at $30.98. In approximately 2 weeks, Acorda Therapeutics has returned 18.30% as of today's recent price of $36.65.
Acorda Therapeutics to Present at the Cowen & Company 34th Annual Health Care Conference
Business Wire - Wed Feb 26, 6:00AM CST
Acorda Therapeutics, Inc. (Nasdaq:ACOR) announced that Ron Cohen, M.D., Acorda's President and Chief Executive Officer, and Mike Rogers, Acorda's Chief Financial Officer, will present at the Cowen & Company 34th Annual Health Care Conference on Monday, March 3 at 4:10 pm ET at the Marriott Copley Plaza Hotel in Boston.
BioLineRx appoints Dr Sandra Panem to board
M2 - Tue Feb 25, 5:59AM CST
Biopharmaceutical company BioLineRx (NASDAQ:BLRX)(TASE:BLRX), headquartered in Israel, revealed on Monday the addition of Dr Sandra Panem PhD to its board of directors.
BioLineRx Appoints Dr. Sandra Panem to Board of Directors
PR Newswire - Mon Feb 24, 6:00AM CST
BioLineRx (NASDAQ: BLRX; TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and developing promising therapeutic candidates, announced today the appointment of Sandra Panem, Ph.D., to its Board of Directors.
Acorda Up After Q4 Earnings - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 18, 1:53PM CST
Acorda misses Q4 earnings estimates
Acorda Therapeutics to Present at Citi 2014 Global Healthcare and RBC Capital Markets Conferences in February
Business Wire - Tue Feb 18, 6:00AM CST
Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that it will present at the Citi 2013 Global Healthcare and RBC Capital Markets conferences in February.
Acorda Therapeutics (ACOR) Soars: Stock Adds 10% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 14, 7:51AM CST
Acorda Therapeutics, Inc. was a big mover last session, as its shares rose over 10% on the day.
Left Ventricular Dysfunction - Pipeline Review, H2 2013 Research Report
M2 - Fri Feb 14, 2:51AM CST
Research and Markets (http://www.researchandmarkets.com/research/45g5zb/left_ventricular) has announced the addition of the "Left Ventricular Dysfunction - Pipeline Review, H2 2013" report to their offering. 'Left Ventricular Dysfunction - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Left Ventricular Dysfunction, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Left Ventricular Dysfunction. Scope - A snapshot of the global therapeutic scenario for Left Ventricular Dysfunction. - A review of the Left Ventricular Dysfunction products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Left Ventricular Dysfunction pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Key Topics Covered: List of Tables List of Figures Introduction Left Ventricular Dysfunction Overview Therapeutics Development Pipeline Products for Left Ventricular Dysfunction - Overview Pipeline Products for Left Ventricular Dysfunction - Comparative Analysis Late Stage Products Clinical Stage Products Early Stage Products Assessment by Monotherapy Products Drug Profiles carvedilol CR - Drug Profile carvedilol CR - Drug Profile omecamtiv mecarbil - Drug Profile bromocriptine - Drug Profile CAP-1002 - Drug Profile cimaglermin alfa - Drug Profile CPI-003 - Drug Profile DIOHF - Drug Profile carvedilol CR - Drug Profile Product Description Mechanism of Action R&D Progress Featured News & Press Releases Companies Mentioned Amgen Inc. Acorda Therapeutics, Inc. Innopharmax Inc. RedHill Biopharma Ltd. Capricor Therapeutics, Inc. For more information visit http://www.researchandmarkets.com/research/45...entricular About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Acorda Therapeutics, The Medicines Co. and Shire Plc Could Be Big Movers in Healthcare Today
George Budwell, The Motley Fool - Motley Fool - Thu Feb 13, 8:36AM CST
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Good morning, fellow Foolish investors! It's time to check in...
Acorda Therapeutics Reports Fourth Quarter and Full Year 2013 Financial Results
Business Wire - Thu Feb 13, 5:00AM CST
--Year-End Cash, Cash Equivalents and Short-Term Investments of $367.2 Million
Will Zoetis (ZTS) Miss Estimates in Q4? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Feb 10, 11:50AM CST
Zoetis is set to report fourth quarter and full year 2013 results on Feb 11 before the opening bell.
Acorda Therapeutics to Present at the Leerink Global Healthcare Conference
Business Wire - Fri Feb 07, 6:00AM CST
Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that Ron Cohen, M.D., President & CEO, will present at the Leerink Global Healthcare Conference on Thursday, February 13, 2014 at 11:35 a.m. at The Waldorf Astoria Hotel in New York.
Acorda Therapeutics to Host Conference Call to Discuss Fourth Quarter and Year End 2013 Financial Results on February 13, 2014
Business Wire - Thu Feb 06, 6:00AM CST
Acorda Therapeutics, Inc. (Nasdaq:ACOR) today announced that it will host a conference call and live webcast to report its fourth quarter and year end 2013 financial results on Thursday, February 13 at 8:30 a.m. ET.
Eguana Delivering Strategic Targets: Company Files Annual Financial Statements and Provides Operations Update
Marketwire - Thu Jan 30, 2:35PM CST
Eguana Technologies Inc. (TSX VENTURE: EGT) ("Eguana" or the Company"), a leading supplier of high performance power conversion and control systems for "smart grid" and "micro-grid" energy storage applications announced that it has filed its Consolidated Financial Statements for the year ending September 30, 2013, along with Management's Discussion and Analysis thereof. The Consolidated Financial Statements and the Management Discussion and Analysis thereof are available on SEDAR at www.sedar.com and on the Company's website at www.eguanatech.com.
Jazz Pharmaceuticals Isn't Tired of Spending Money
Todd Campbell, The Motley Fool - Motley Fool - Tue Jan 14, 5:30PM CST
Jazz Pharmaceuticals, which spent nearly $1 billion buying orphan drug maker Gentium in December, just inked another deal to lock up Aerial BioPharma's promising mid stage narcolepsy drug, ADX-N05 Jazz is giving Ariel -- a small...
ACOR Preliminary Q4 Revs Look Good - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Jan 14, 10:40AM CST
Ampyra sales improved on a sequential basis.
(0)
(0)Acorda Therapeutics Inc. (ACORQ) Stock Research Links
Scroll down for more posts ▼